Please assess the completion status of the following clinical trial:

Trial Title: WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* All patients (both genders) with a clinical diagnosis of BUD (categories: I and II, cross-sectional diameter ≤ 10cm) as agreed by study site treatment team led by the lead clinicians~Exclusion criteria:~1. Patients with lesion sizes \>10cm in cross-sectional diameter~2. Children \< 5 years, or \< 20 kilograms body weight~3. Pregnancy (self-reported, clinically diagnosed, or urine test (beta-hCG) positive~4. Patients with previous treatment of Buruli ulcer, tuberculosis or leprosy with at least one of the study drugs (rifampicin, streptomycin, clarithromycin)~5. Patients with history of hypersensitivity to rifampicin and/or streptomycin and/or clarithromycin~6. Patients with previous treatment with macrolide or quinolone antibiotics, or antituberculosis medication, or immuno-modulatory drugs including corticosteroids within one month~7. Patients with current treatment with any drugs likely to interact with the study medication, e.g, anticoagulants, cyclosporin, phenytoin, and phenobarbitone. Users of oral contraceptives should be notified that such contraceptive is less reliable if taken with rifampicin; alternative (mechanical) contraceptive methods will be discussed with the study participant~8. Patients with co-infection with HIV~9. Patients with history or having current clinical signs of ascites, jaundice, partial or complete deafness, myasthenia gravis, renal dysfunction (known or suspected), diabetes mellitus, and severe immune compromise (e.g., immunosuppressive drugs after organ transplant), or evidence of (previous) tuberculosis, Buruli ulcer or leprosy; or terminal illness (e.g., metastasized cancer)~10. Patients who are unable to take oral medication or having gastrointestinal disease likely to interfere with drug absorption~11. Patients with known or suspected bowel strictures who cannot tolerate macrolide antibiotics such as clarithromycin~12. Patients with mental condition, including addiction with substance abuse (alcohol, qat, etc) likely to interfere with possibility to comply with the study protocol~13. Patients who are not willing to give informed pre-consent, and consent (patient and/or parent/legal representative), or withdrawal of consent

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SR8 (Type: ACTIVE_COMPARATOR): Streptomycin (S: 15 mg/kg per day, intramuscularly) in combination with rifampicin (R: 10 mg/kg per day, orally) for 8 weeks
- CR8 (Type: EXPERIMENTAL): Clarithromycin (C: 15 mg/kg per day, oral extended release formulation) in combination with rifampicin (10 mg/kg per day, orally) for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).